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A single nucleotide polymorphism, C1858T, in the gene encoding the protein tyrosine
phosphatase nonreceptor type 22 (PTPN22) results in one of the strongest genetic traits
associated with autoimmune disease outside of the Major Histocompatibility Complex
(MHC) genes. However, the consequences of this polymorphism, which introduces
an arginine to tryptophan substitution at amino acid 620, for the function of PTPN22
protein is unclear and conflicting results have been obtained in human compared to
mouse cells expressing this variant phosphatase. In mouse the variant appears to be
a loss-of-function allele resembling a milder form of the null allele, while studies in
human cells have reported it to be a gain-of-function mutation. To address whether
the phosphatase has distinct functions in mouse vs. human T cells, we used CRISPR
gene-editing to generate the first example of human PTPN22-KnockOut (KO) T cells.
By comparing isogenic human T cells which express or lack PTPN22, we showed that
PTPN22 KO T cells displayed enhanced expression of IL-2 and CD69 upon stimulation
with cognate antigen. PTPN22 KO cells also showed increased Erk phosphorylation
upon stimulation with weak antigen, but the difference was diminished in response
to strong antigen, indicating that PTPN22 plays a more critical role in regulating
weak-antigen responses. These data are in keeping with a role for PTPN22 in determining
the threshold of stimulation required to activate T cells, a critical function of autoimmune
pathogenesis. Our data indicate that PTPN22 has comparable functions in mouse and
human T cells, and that the conflicting results in the literature regarding the impact of
the point mutation are not due to differences in the activity of PTPN22 itself, but may be
related to interactions with other proteins or splice variation.
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INTRODUCTION
The protein tyrosine phosphatase nonreceptor type 22 (PTPN22) exhibits a common single
nucleotide polymorphism (SNP), C1858T, which has been strongly linked with autoimmune
disorders. Genome-wide association studies have connected the PTPN22C1858T SNP with increased
susceptibility to numerous autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis, and
systemic lupus erythematous, suggesting the variant allele plays a role in a common pathway in
autoimmune development, however the mechanism behind the association is as yet unknown (1).
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One aspect of the role of PTPN22 in autoimmune diseases
may lie in its function in T cells. Mice deficient in PTPN22 exhibit
enhanced T cell receptor responses, expanded effector/memory
T cell populations, and enlarged germinal centers (2). PTPN22
acts as a negative regulator of T cell receptor signaling by
dephosphorylating activating tyrosine residues on the proximal
signaling molecules Lck, Fyn, and Zap-70 (3). PTPN22 has been
shown to be particularly important in regulating responses to
weak peptide stimulation in mouse T cells thus modulating
self-reactivity without impairing responses to pathogens (4).
The autoimmune-associated SNP converts arginine 620
to a tryptophan (R620W) in a region of PTPN22 that
mediates interaction with other proteins, and greatly reduces its
association with another negative regulator of T cell signaling,
C-terminal Src kinase (Csk). The functional significance of the
loss of association between PTPN22 and Csk and its impact
on autoimmune predisposition remains unresolved. Studies
of the homologous mutation in mouse models have clearly
demonstrated that the autoimmune-associated SNP is loss-of-
function, leading to a reduced ability of PTPN22 to downregulate
T cell responses: T cells isolated from these mice have enhanced
activation profiles and cytokine production (5, 6), similar to
observations in mice lacking PTPN22 altogether (2). However,
many studies of human T cells expressing the PTPN22 R620W
variant allele have yielded the opposite result: PTPN22 R620W
appears to have a stronger negative regulatory effect, that is, it acts
as a gain-of-function mutation compared to the more common
form of the protein, resulting in reduced T cell effector functions
(7, 8). On the other hand, PTPN22 R620W appeared to have a
loss-of-function effect in the context of myasthenia gravis (9),
and Zikherman et al demonstrated that overexpression of Csk as
well as PTPN22 R620W revealed a loss-of-function effect for the
SNP (10). Thus, the functional significance of the PTPN22R620W
mutation in human is not as straightforward as the clear loss-
of-function effect seen in mice carrying the equivalent PTPN22
R619W alleles.
A possible source of the conflicting results in studies
of human PTPN22 is the inability to compare the normal
effects of the protein on a genetically identical background.
Instead studies have either relied on material from genetically
and environmentally distinct individuals, on overexpression of
PTPN22 in cell lines, which alters the normal stoichiometry
of the protein, or on siRNA knockdown methods or chemical
inhibitors, which carry concerns regarding possible off-target
effects.
Here, we address the challenges in studying the function of
human PTPN22 by using CRISPR to create isogenic human T cell
lines with PTPN22 knocked out at the genomic level, enabling
us to isolate the effects of human PTPN22 on T cell signaling
and compare whether it has a similar function to that seen in
mouse T cells. We found that the role of PTPN22 in human T
cell regulation is indeed similar to that in mice, in that its absence
leads to enhancement of T cell signalingmarkers, especially in the
context of weak antigen stimulation. These findings suggest that
the discrepancies reported in the literature regarding the function
of mouse and human PTPN22R620W are not a consequence of
distinct functions of the common allelic variant of the protein.
MATERIALS AND METHODS
Cell Lines
TCR−/− Jurkat cells and Phoenix-AMPHO cells were obtained
from Hans Stauss, University College London. Cells were
maintained in IMDM (Sigma-Aldrich) media supplemented with
5% heat- inactivated FBS (Serotec), 2 × 10−3 M L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, and 5 × 10−5 M
2-mercaptoethanol (Sigma-Aldrich). Retroviral transduction of
TCR constructs was performed as described (11).
Antibodies
Antibodies used for T cell stimulation included DimerX
I recombinant HLA-A2 Ig (BD Biosciences), CD3 (clone
OKT3, Biolegend), and CD28 (clone CD28.2, Biolegend).
Western blot antibodies included PTPN22 (clone D6D1H,
Cell Signaling Technology), Lck (Cell Signaling Technology),
Zap-70 (Cell Signaling Technology), α-tubulin (clone TU-
02, Santa Cruz), anti-rabbit Ig (Life Technologies) and
anti-mouse Ig (LI-COR). For IP-FCM, the Akt capture
antibody used was clone SKB1 (Merck Millipore), total Akt
was detected using clone 53G (Cell Signaling Technology),
and phospho Akt S473 was detected using clone D9E
(Cell Signaling). Flow cytometry antibodies included CD69
(clone FN50, BD Biosciences), Il-2 (clone MQ1-17H12,
Biolegend), pSrc family Y416 (Cell Signaling Technology),
Lck pY505 (Cell Signaling Technology), Zap-70 pY493 (Cell
Signaling Technology), Erk 1/2 pY204 (clone 197G2, Cell
Signaling Technology), NFAT (clone D43B1, Cell Signaling
Technology), cFos (clone 2G2, Novus Biologicals), an anti-rabbit
secondary (Invitrogen), and an anti-mouse secondary (Life
Technologies).
CRISPR Transfection
Cas9 plasmids Px330 and Px461 were purchased from Addgene
and guide sequences were annealed as described (12). Neon
transfection of plasmids into cells was carried out as per
manufacturer protocol for Jurkat cells (Thermo Fisher).
T Cell Stimulation
Stimulating peptides used were the HLA-A2-binding peptides
pTax (LLFGYPVYV) and pHuD (LGYGFVNYI). DimerX IHLA-
A2 Ig (BD Biosciences) was incubated overnight with 160
molar excess of peptide. Plates were coated with 20µg/ml of
DimerX+peptide or anti-CD3ε antibody. 2µg/mL anti-CD28
was included in media for stimulation.
T Cell Signaling Assays
Intracellular cytokine staining was performed using the BD
Cytofix/Cytoperm kit. Samples for phosphoprotein flow
cytometry were prepared according to BD Phosflow protocol
before being stained with primary and secondary antibodies.
For qPCR, RNA was isolated by Trizol and isopropanol
precipitation. 1 µg of RNA was used for each reverse
transcription reaction. qPCR mix was prepared according to
SYBR Green manufacturer protocol (Thermo Fisher).
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qPCR Primers
IL-2: CTTGCATTGCACTAAGTCTTGC & TAAATGTGAGCA
TCCTGGTGAG;
cFos: CCGGGGATAGCCTCTCTTACT & CCAGGTCCG
TGCAGAAGTC;
cJun: CCTTGAAAGCTCAGAACTCGGAG & TGCTGC
GTTAGCATGAGTTGGC
EGR-1: CTTCAACCCTCAGGCGGACA & GGAAAAGCG
GCCAGTATAGGT
Akt analysis by immunoprecipitation of protein complexes by
flow cytometry (IP-FCM) (13), western blotting, and calcium flux
protocols have been previously described (14).
Nucleus Flow Cytometry
Samples were stained using the recently described protocol (15).
Briefly, samples were kept on ice unless otherwise noted. Cell
pellets were resuspended in sucrose buffer containing 320mM
sucrose, 10mMHEPES pH 7.8, 8mMMgCl2, 0.1% Triton-X 100,
and 1x Protease Inhibitor (Sigma-Aldrich P8340) and incubated
for 15min. Samples were then centrifuged at 2,000× g for 10min
at 4◦C. Pellets washed twice in washed in sucrose buffer lacking
Triton-X. Nuclei were fixed by resuspending in sucrose buffer
lacking Triton-X and containing 4% paraformaldehyde, and
incubating for 25min at room temperature, protected from light.
Fixed nuclei were washed once with FACS buffer supplemented
with 8mM MgCl2 and centrifuged at 1,000 × g for 5min
at 4◦C, then washed again and stained with flow cytometry
antibodies diluted in PBS containing 2% FCS, 8mM MgCl2,
and 0.3% Triton-X 100. After staining, samples were washed
and resuspended in FACS buffer containing MgCl2 for flow
analysis.
RESULTS
Generation of PTPN22 KO Jurkat Clones
We described previously that the impact of loss of PTPN22 in
mouse OT-1 T cells varied depending on the strength of the
stimulating pMHC ligand (4). In order to create a human T cell
model which could be stimulated with strong and weak affinity
peptides, we transduced TCR−/− Jurkat cells with retrovirus
encoding a TCR that has strong affinity for a pTax peptide
(LLFGYPVYV, derived human T-lymphotropic virus type 1)
and weak affinity to the pHuD peptide (LGYGFVNYI, derived
from human neuronal protein), both of which are HLA-A2
restricted (11). Transduced cells were sorted for expression of
Tax TCR and single cells cloned by limiting dilution. Clonal
populations were expanded and tested for upregulation of
activationmarkers when stimulated with pTax peptide. One clone
with high expression of Tax TCR and reliable responsiveness
to pTax was selected to serve as the parent line for CRISPR
experiments.
The selected Tax TCR Jurkat clone was used for transfection
with plasmids containing Cas9, sgRNA sequences targeting
PTPN22 Exon 1, and a GFP reporter. A transfection was
also performed on the same cells using only a GFP reporter
construct to generate PTPN22 wild-type controls which have
undergone the same manipulation (sgRNA sequences listed
in Supplementary Figure 1). In both cases, GFP positive cells
were sorted singly into wells and clonal populations were
expanded. An initial screen was performed by PCR of the
PTPN22 exon 1 region, and clones with visible shifts in the
size of the PCR product were selected for further screening
by western blot. An indel frequency of 70% was estimated
based on the initial PCR screens. Western blot revealed that
PTPN22 protein expression was completely lost in approximately
half of the selected the clones, and we found that loss
of PTPN22 expression did not influence expression of its
known interactors Lck or Zap-70 (Figure 1A). The PTPN22
Exon 1 region of the clones was sequenced to confirm the
deletion and similar expression of Tax TCR to the parent
line was confirmed for each clone (Supplementary Figure 2).
Six PTPN22 WT and six KO clones were selected for further
studies.
PTPN22 Does Not Affect Steady-State
Survival of Jurkat Cells
PTPN22 wild-type (WT) and knockout (KO) clones were
identical in size and granularity as assessed by FACS analysis of
forward and side scatter (Figure 1B). We detected no differences
in growth of cultures between PTPN22 WT and KO Jurkat
clones (Figure 1C), in contrast to the report by Baghbani et al.,
who found that siRNA disrupting PTPN22 transcription caused
apoptosis in Jurkat cells (16). Baghbani et al. attributed their
observations to reduction in phosphorylation of Akt in cells
treated with PTPN22 siRNA, however we observed no alterations
in Akt phosphorylation between PTPN22 WT and KO clones as
assessed by IP-FACS (Figure 1D). As the maintenance of Jurkat
cells in culture is a TCR-independent process it is perhaps not
surprising that PTPN22 is not relevant in this context.
Increased IL-2 and CD69 Expression in
PTPN22 KO Jurkat Cells
To determine the effect of PTPN22 on Jurkat T cell responses,
we evaluated the upregulation of IL-2 and CD69 in response to
cognate peptide. We loaded DimerX, a fusion protein linking
human HLA-A2 to the variable heavy region of mouse IgG1,
with pTax peptide and used this reagent bound to plastic 96-
well plates to provide peptide-MHC stimulation of the clones.
IL-2 and CD69 expression were evaluated by intracellular flow
cytometry after 6 h of stimulation with DimerX+ pTax in media
containing anti-CD28 and Brefeldin A (Figure 2A).
We observed dose dependent upregulation of both IL-2
and CD69 after 6 h of stimulation and found that both were
significantly higher in PTPN22 KO clones compared with
PTPN22 WT clones. Increased responsiveness of PTPN22 KO
clones was found at all concentrations of the antigen and with
the PHA+PMA positive control stimulus (Figure 2B). PTPN22
KO clones also showed marginally elevated CD69 expression in
the absence of stimulation, but this was much smaller than was
observed following stimulation. The increase in expression of
T cell activation markers in PTPN22 KO clones is similar to
observations made in Ptpn22−/− mice (2, 4, 17) and confirms
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that PTPN22 acts as a negative regulator in human T cells
comparably to its role to mouse T cells.
To determine whether the increase in IL-2 production was
driven by increased transcription, we measured the amount of
IL-2 message by qPCR (Figure 2C). PTPN22 WT and KO clones
were stimulated for 4 h with DimerX+ pTax in media containing
anti-CD28. We found that PTPN22 KO clones had significantly
greater levels of IL-2 message (reduced CP-values), indicating
that the increase in IL-2 expression can be attributed to increased
transcription rather than any post-transcriptional regulation of
mRNA.
Altered Responsiveness of PTPN22 KO
Cells Is Not Detectable in Early TCR
Signaling Pathways
Given that IL-2 transcription was upregulated in PTPN22 KO
cells we sought to determine which specific TCR signaling
pathways in the Jurkat clones might be enhanced by loss
of PTPN22. The early signaling molecules Lck, Fyn and
Zap-70 are known targets for PTPN22 phosphatase activity
(3). We used phosphoprotein flow cytometry to check for
differences in Lck and Zap-70 phosphorylation. DimerX HLA-
A2 + pTax stimulation did not produce sufficient changes in
phosphorylation of Lck and ZAP-70 to be detectable by FACS,
possibly because this stimulus was be too weak or transient.
Instead we used plate-bound anti-CD3 to stimulate the clones
which does produce changes in phosphorylation of Lck and ZAP-
70 which are detectable by FACS. In order to control for well to
well variation in stimulation, two independently derived PTPN22
WT and two PTPN22 KO clones were differentially labeled with
CellTrace Violet (CTV) and stimulated together in each well,
so that the four clones were treated with identical stimulation
and staining conditions (Figure 3A). Which individual clones
were labeled with the different dye concentration was varied
randomly between experiments to exclude any effects of the
dye on the response or the detection of phosphorylated
substrates.
A representative example of the staining from a single well
is shown in Figure 3A. Although there was clear shift in the
FIGURE 1 | PTPN22 does not affect steady-state survival of Jurkat cells. (A) Expression of PTPN22, Zap-70, and Lck in 3 PTPN22 WT and 6 independently derived
KO Jurkat clones were evaluated by Western blot, probed sequentially with Abs to PTPN22, Zap70, Lck, and β-actin as loading control. (B) No differences in cell size
or granularity were observed between PTPN22 WT and KO Jurkat clones by flow cytometry in a representative clone of each. (C) PTPN22 WT and KO Jurkat clones
were grown in culture and the number of cells was counted daily. Data is representative of two independent experiments. (D) Constitutive phosphorylation of AKT was
evaluated by IP-FCM. The MFI of pAKT was normalized to the MFI of total AKT for each IP. Data from two independent experiments is shown.
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FIGURE 2 | Increased IL-2 and CD69 expression in PTPN22 KO Jurkat cells. (A) Example dot plots of intracellular staining of representative Jurkat clones after 6 h
DimerX+pTax stimulation. (B) Upregulation of IL-2 and CD69 in Jurkat clones was evaluated by intracellular staining and flow cytometry after 6 h of DimerX+pTax
stimulation. Data represents three independent experiments which each included six clones of each genotype (n = 6). Each point represents a single clone in an
experiment. (C) IL-2 mRNA was measured by qPCR after 4 h incubation with the indicated stimuli. Data represents three independent experiments which included
three clones of each genotype (n= 3). Statistical significance for each condition was determined by unpaired T-test and Bonferroni multiple comparisons correction. A
p < 0.05 was considered significant. ns, not significant, *p< 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 3 | Lack of detectable changes in proximal signaling pathways in PTPN22 KO Jurkat cells. (A) Phosphorylation of Lck and Zap-70 tyrosine residues was
evaluated by phosphoprotein flow cytometry after stimulation with αCD3 for the indicated time periods. CellTrace Violet tagging of PTPN22 WT and KO clones
stimulated and stained in the same well is shown as a representative dot plot. Pooled data from three independent experiments is shown. (B) Calcium flux was
evaluated by Indo-1 staining. Peak value, peak time, and slope of calcium flux upon stimulation with αCD3 were quantified and compared between PTPN22 WT and
KO clones. Data from two independent experiments is shown. (C) Translocation of transcription factors was evaluated using nuclear flow cytometry after
DimerX+pTax stimulation for the indicated time periods. Data from three independent experiments is shown. (D) Transcription of immediate early genes was evaluated
by qPCR after CD3 stimulation for the indicated time periods. Data from four independent experiments is shown.
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staining of stimulated clones (red and blue dots) compared to
unstimulated (black dots) or inhibited (PP2-treated, gray dots)
clones, the variance in the responses of individual clones
in different experiments overall was too high to see any
statistically significant changes between PTPN22 WT and KO
cells. However, there was a very slight but consistent increase in
the average phosphorylation of residues in stimulated PTPN22
KO cells, although this did not reach statistical significance. It
is possible that the assay was not sensitive enough to report
subtle differences in early transient phosphorylation events.
These results are in keeping with our previous data (18) with
primary mouse T cells which, following stimulation, showed
only small changes in phosphorylation of these early kinases
between WT and PTPN22 KO T cells with considerably less
variance between samples than observed with these Jurkat clones.
However, while the slight differences in early signaling molecule
phosphorylation were not statistically significant, they might still
have biological relevance and to be responsible for the changes in
IL-2 production which are further downstream.
Calcium signaling was reported to be enhanced in
PTPN22−/− mouse T cells (10, 14, 19) and to be diminished in
Jurkat cells overexpressing PTPN22 (8). To compare calcium
signaling in PTPN22WT and KO clones, we differentially labeled
one clone of each genotype with CFSE, loaded both with Indo-1,
and analyzed calcium flux in response to saturating amounts of
aqueous anti-CD3 stimulation. We analyzed three parameters:
peak value, the maximum ratio of violet to blue Indo-1 reached
by a clone; peak time, the number of seconds until a clone
reached its peak value; and slope, the rate at which the ratio of
violet to blue Indo-1 returned to baseline. All three parameters
were equivalent for each individual clone and data for the peak
value and slope are shown in Figure 3B. Fifteen minutes after
the addition of anti-CD3, cells were treated with ionomycin to
observe the maximum flux per clone.
Although there was variation in the Ca2+ flux between
individual clones stimulated together in the same well, this
appeared to be clone specific and unrelated to the presence
or absence of PTPN22. Overall no significant differences in
calcium flux were detected when the data was pooled for multiple
PTPN22 WT and KO clones tested for any of the parameters
analyzed (Figure 3B). Once again there was a slight trend for
PTPN22 KO clones to cluster toward the higher range of peak
calcium flux value, which likely accounts for the slightly steeper
slope as they returned to baseline, but overall the variance was
such that this difference was not statistically significant.
Many pathways of TCR signaling culminate in the activation
of the transcription factors NFAT, and AP-1, and their
translocation into the nucleus, which is a key event for cytokine
production. To determine whether enhanced translocation
of these transcription factors occurred in PTPN22 KO vs.
WT clones, we isolated nuclei from stimulated cells and
analyzed them for the presence of NFAT1 and cFos by flow
cytometry (15). We observed clear translocation of NFAT
and cFos into the nucleus following stimulation which was
inhibited by pre-treatment of the cells with PP2 indicating the
translocation was linked to activation (Figure 3C). Surprisingly
we did not see any difference between PTPN22 WT and
KO clones over the time course of stimulation that was
analyzed. It was puzzling that the increased frequency of IL-
2 producing cells amongst the PTPN22 KO clones (Figure 2C)
did not correlate with an increased nuclear import of
key transcription factors known to be important for IL-2
transcription, however, presence of a transcription factor in the
nucleus does not guarantee increased transcriptional activity of
a particular genetic locus and furthermore only one member
of each transcription factor family was analysed in this set of
experiments.
To further investigate transcriptional activity triggered by
TCR signaling, we used qPCR to compare the transcript
abundance of immediate early genes, cJun, cFos and EGR1 in
PTPN22 WT and KO clones. In this assay, a lower value for
the crossing point (CP) cycle indicates more mRNA in the
sample. Instead of normalizing values to a housekeeping gene,
the abundance of which we found to fluctuate upon stimulation
(Supplementary Figure 3), we normalized the loading of each
cDNA reaction to an input concentration of 1 µg RNA. Again,
no significant differences in the transcription of immediate early
genes were detected between PTPN22 WT and KO clones,
although a very slight trend was observed toward PTPN22
KO clones having lower CP-values and thus more mRNA
(Figure 3D).
PTPN22 Has a Greater Regulatory Effect
on T Cell Responses to Weak Stimulus
Previous reports have suggested that PTPN22 may be more
critical in regulating T cell responses to low-affinity stimulus
in mouse (4). To test whether this function of PTPN22 is
conserved in human T cells, we assayed Erk phosphorylation.
pErk was consistently detected in over 90% of stimulated Jurkat
cells and continued to be clearly detectable even after very weak
stimulation, making it an ideal readout to study low-affinity
peptide stimulation. As before, for consistency of stimulation,
individual clones were labeled with varying concentrations of
CellTrace Violet so that they could be activated and stained in the
same well. 1-h stimulations were performed using titrations of
plate-bound DimerX containing either pTax or the weak affinity
peptide pHuD and pErk was measured by phosphoprotein flow
cytometry (Figure 4A).
We found that frequency of cells expressing pErk was
increased significantly in PTPN22 KO clones compared with
WT clones, particulary in conditions of weak stimulation
such as with the low affinity peptide pHuD or with low
concentrations of the higher affinity pTax peptide. However,
the difference between PTPN22 WT and KO responses
was lost as stimulation strength increased (Figure 4B),
demonstrating that PTPN22 KO clones specifically showed
enhanced responses to weak stimuli, compared to PTPN22
WT clones. As we showed with mouse CD8T cells, these
results indicate that human PTPN22 is more significant
in regulating T cell responses to weak peptide stimulation,
but that its regulation is overridden as signal strength
increases. Stimulation by weak antigen are critical drivers
of autoimmune and cancer responses, thus this function of
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FIGURE 4 | PTPN22 dampens ERK phosphorylation particularly in response to weak stimuli. (A) Representative histograms of phosphorylation of Erk Y204 in Jurkat
clones, evaluated by phosphoprotein flow cytometry following 1 h of stimulation with the indicated amount of DimerX + peptide. Clones were tagged with CellTrace
Violet and stimulated and stained in the same well. (B) Data from two independent experiments is shown. Statistical significance for each condition was determined
by unpaired T-test and Bonferroni multiple comparisons correction. A p < 0.05 was considered significant. ns, not significant, *p < 0.05.
PTPN22 may be highly relevant to the development of these
diseases.
DISCUSSION
We demonstrate here that the absence of PTPN22 in Jurkat
cells leads to enhancement of certain T cell responses. Our
findings showed that IL-2 and CD69 upregulation in response
to stimulation was significantly enhanced in human T cells
lacking PTPN22, which was similarly observed in mouse T cells
(4, 14, 17, 20), suggesting that PTPN22 downregulates similar
pathways of TCR signaling in human and mouse cells. Our data
corroborated those from Perri et al. (21), who reported increased
IL-2 expression in human T cells treated with PTPN22-siRNA.
The evidence therefore supports a negative regulatory role for
human PTPN22 of the pathways leading to IL-2 induction in T
cells.
Given the clear increase in IL-2 producing cells amongst the
PTPN22 KO clones, it was surprising that we could detect little
evidence of differences in the upstream signaling pathways or
activation of transcription factors leading to IL-2 production.
However, the assays used to monitor signaling are, by and large,
fairly insensitive. Anti-CD3 stimulation or saturating amounts
of DimerX were often needed to acquire a signal above the
detection threshold particularly in assays requiring short term
stimulations including phosphorylation of proximal substrates
such as Lck and ZAP-70 or Ca2+ flux. These concentrations of
stimuli are on the upper plateau of the response where differences
in the responses between two populations may be masked. There
was also a wide variance of response in many of these assays
between individual clones on different days, despite our attempts
to minimize this variance by stimulating multiple individually
labeled clones in a single well where possible. In contrast, we were
able to detect differences between PTPN22 WT and KO clones
using assays which report more downstream events such as
ERK phosphorylation, IL-2 production and CD69 upregulation,
indicating that the presence of PTPN22 in WT cells serves to
modulate these responses and thismodulationwasmost apparent
following weaker stimulation.
We reported previously that weak stimulation led to stronger
responses in PTPN22 knockout mouse OT-1 T cells, and the
influence of loss of PTPN22 was reduced with increased
stimulation strength (4). Our data here suggests that human
PTPN22 has a greater regulatory effect on T cell signaling in
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contexts of weak peptide stimulation also. Thus, in human and
in mouse, PTPN22 serves to differentiate weak TCR stimulation
from strong stimulation, and specifically downregulates T cell
signaling in the former situation. Whether there is a specific
mechanism regulating PTPN22 activity according to stimulation
strength or whether PTPN22 simply provides relatively weak
negative regulation which is overruled by strong stimulus
remains to be seen.
Based on our findings, the reported discrepancies between
PTPN22 R620W studies in humans and mice, in which the
former was reported to be a gain-of-function mutation (7, 8)
while the latter showed a loss-of-function (5, 6) are unlikely to
be due differences in the normal activity of full-length PTPN22,
but perhaps instead to its interactions with other regulatory
proteins that have yet to be fully described. Another possible root
of the controversy between the conflicting mouse and human
PTPN22R620W data may be related to the reported presence
of different isoforms of PTPN22 expressed by human T cells
(22, 23). In contrast our Jurkat clones and mouse T cells appear
to express only the full-length protein as determined by western
blot. The roles of the various isoforms of human PTPN22 are only
partially elucidated (22, 23), and may have different effects on the
function of PTPN22 in individuals expressing the R620W variant
allele. For example, Chang et al described a dominant negative
isoform of human PTPN22, overexpression of which increased
production of IL-2 in Jurkat cells (24). Additionally, differences
in PTPN22 isoform ratios have been reported in patients with
rheumatoid arthritis and systemic lupus erythematosus (25, 26).
It is possible that these isoforms lend functions to human
PTPN22 that are absent in mouse and Jurkat T cells, and which
may be differentially affected by the R620W polymorphism.
The ability to knockout signaling molecules in human T
cells using Crispr/Cas provides an unprecedented opportunity
to compare the function of such molecules between mouse and
human T cells. In the case of PTPN22, the data from the analysis
of knockout cells reported here suggest this phosphatase has a
similar function in both species to modulate T cell signaling.
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